Genmab A (GMAB) Non Operating Income (2018 - 2026)
Genmab A (GMAB) reported Non Operating Income of -$106.0 million for Q1 2026, down 289.29% on a YoY basis from $56.0 million in Q1 2025, and down 560.87% quarter-over-quarter from $23.0 million in Q3 2025.
Genmab A (GMAB) Non Operating Income (2018 - 2026) Analysis & Trends
Genmab A has reported Non Operating Income for 6 years, with the latest figure at -$106.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 289.29% year-over-year to -$106.0 million; the trailing twelve-month figure through Mar 2026 stood at -$84.0 million (down 163.64% YoY), and the FY2025 full-year result was $139.0 million, down 60.73% from the prior year.
- Non Operating Income for Q1 2026 stood at -$106.0 million, down from $23.0 million in the prior quarter.
- The five-year high for Non Operating Income was $133.0 million in Q1 2024, with the low at -$106.0 million in Q1 2026.
- Historically, Non Operating Income has averaged $9.8 million across 3 years, with a median of $23.0 million in 2025.
- Annual changes were most pronounced in 2025 — Non Operating Income surged 140.35% — and 2026, when it slumped 289.29%.
- Genmab A's Non Operating Income stood at -$57.0 million in 2024, then surged by 140.35% to $23.0 million in 2025, then tumbled by 560.87% to -$106.0 million in 2026.
- The last three Non Operating Income figures came in at -$106.0 million (Q1 2026), $23.0 million (Q3 2025), and $56.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 9.35 Mn |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | -106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 23.00 Mn |
| Mar 31, 2025 | 56.00 Mn |
| Sep 30, 2024 | -57.00 Mn |
| Mar 31, 2024 | 133.00 Mn |
| Sep 30, 2020 | -187.00 |
| Dec 31, 2019 | 348.00 |
| Sep 30, 2019 | 348.55 Mn |
| Dec 31, 2018 | 30.43 Mn |